{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:46:21Z","timestamp":1782773181013,"version":"3.54.5"},"reference-count":33,"publisher":"Endocrinology Research Centre","issue":"6","license":[{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>\n                    <jats:bold>BACKGROUND:<\/jats:bold>\n                    The prevalence of SHPT depends on control strategy and target level of PTH. There is insufficient data for a justified choice of goals and strategy for the SHPT correction.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>AIM:<\/jats:bold>\n                    A retrospective, multicenter, cohort study was conducted to assess the ethelcalcetide efficacy after six months in real world practice. The study sought to identify whether MBD-CKD characteristics are predictive of achieving the goals.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>MATERIALS AND METHODS:<\/jats:bold>\n                    A study included 302 patients in 20 dialysis units in St. Petersburg. The primary endpoint was the proportion of patients who reached the target of PTH (300\u2013599 pg\/ml). The secondary endpoint was an absolute and relative decrease in PTH. The results were compared in subgroups with PTH (&lt;600, 600\u20131000, \u22651000 pg\/ml) and with and without signs of parathyroid authonomy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    In patients aged 56 (12) years (men \u2014 61%) with a dialysis duration of 36 (Q1-Q3 23-55) months with baseline PTH level of 729 (548\u2013957) pg\/ml and with calcemia and phosphatemia 2.35 (0.25) and 1.97 (0.47) mM\/L, the proportion of success was 49.7%. It is more expected for the PTH of 600\u20131000 pg\/ml compared with PTH&gt;1000 pg\/ml: 79% vs. 36%,\u00a0p&lt;0.001. In presence of signs of parathyroid authonomy, 48% reached the target range vs. 86% in its absence (p&lt;0.001) in subgroup with PTH of 600\u20131000 pg\/ml. For patients with PTH above 1000 pg\/ml, the proportion was 25% vs. 58% (p=0.016). The signs of parathyroid authonomy was the most significant independent risk for target achieving (OR=0.3 [95% CI 0.13; 0.68], p=0.004)\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSION:<\/jats:bold>\n                    When transferring patients from cinacalcet to etelcalcetide, no new side effects or drug intolerance were noted. In moderate SHPT (PTH 600\u20131000 pg\/ml) it is possible to achieve the target in most patients, but with higher level, the result worsened. The signs of parathyroid authonomy predicts the insufficient effect better than high baseline PTH level.\n                  <\/jats:p>","DOI":"10.14341\/probl13563","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:17:04Z","timestamp":1769516224000},"page":"4-14","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":1,"title":["Switching patients from cinacalcet to etelcalcetide: evaluation of predictors of efficacy in a retrospective cohort study"],"prefix":"10.14341","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-1824","authenticated-orcid":true,"given":"E. V.","family":"Parshina","sequence":"first","affiliation":[{"name":"Saint Petersburg University, N.I. Pirogov Clinic of High Medical Technologies"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2309-8083","authenticated-orcid":true,"given":"R. P.","family":"Gerasinchuk","sequence":"additional","affiliation":[{"name":"Northwestern State Medical University n.a. I.I.Mechnikov;\r\nCity Mariinsky Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9235-3484","authenticated-orcid":true,"given":"A. Y.","family":"Zemchenkov","sequence":"additional","affiliation":[{"name":"City Mariinsky Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5405-7887","authenticated-orcid":true,"given":"A. B.","family":"Zulkarnaev","sequence":"additional","affiliation":[{"name":"Moscow Regional Scientific Research Clinical Institute n.a. M.F. Vladimirsky"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5458","published-online":{"date-parts":[[2026,1,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Sharma S, Gupta A. Adynamic bone disease: Revisited. Nefrologia (Engl Ed). 2022;42(1):8-14. doi: https:\/\/doi.org\/10.1016\/j.nefroe.2022.03.005","DOI":"10.1016\/j.nefro.2020.11.012"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Elkhouli E, Nagy E, Santos CGS et al. Mixed uremic osteodystrophy: an ill-described common bone pathology in patients with chronic kidney disease. Osteoporos Int. 2023;34(12):2003-2012. doi: https:\/\/doi.org\/10.1007\/s00198-023-06886-5","DOI":"10.1007\/s00198-023-06886-5"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Bernardor J, De Mul A, Bacchetta J, Schmitt CP. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients. Curr Osteoporos Rep. 2023;21(2):193-204. doi: https:\/\/doi.org\/10.1007\/s11914-023-00782-x","DOI":"10.1007\/s11914-023-00782-x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Izzo C, Secondulfo C, Bilancio G et al. Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview. Life (Basel). 2024;14(3):418. doi: https:\/\/doi.org\/10.3390\/life14030418","DOI":"10.3390\/life14030418"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ketteler M, Evenepoel P, Holden RM; Conference Participants. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;107(3):405-423. doi: https:\/\/doi.org\/10.1016\/j.kint.2024.11.013","DOI":"10.1016\/j.kint.2024.11.013"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Liu Y, Yang Q, Chen G, Zhou T. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease. Curr Pharm Des. 2022;28(40):3289-3304. doi: https:\/\/doi.org\/10.2174\/1381612829666221027110656","DOI":"10.2174\/1381612829666221027110656"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Liu X, Liu Y, Zheng P, Xie X, Li Z, Yang R, Jin L, Mei Z, Chen P, Zhou L. Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis. Eur J Clin Pharmacol. 2024;80(10):1555-1569. doi: https:\/\/doi.org\/10.1007\/s00228-024-03730-5","DOI":"10.1007\/s00228-024-03730-5"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Khan BA, Qu X, Hua Y, Javaid MM. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore. Cureus. 2023;15(11):e48186. doi: https:\/\/doi.org\/10.7759\/cureus.48186","DOI":"10.7759\/cureus.48186"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Karaboyas A, Muenz D, Fuller DS et al. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Am J Kidney Dis. 2022;79(3):362-373. doi: https:\/\/doi.org\/10.1053\/j.ajkd.2021.05.020","DOI":"10.1053\/j.ajkd.2021.05.020"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Karaboyas A, Muenz D, Hwang Y et al. Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness. Kidney Med. 2022;4(6):100475. doi: https:\/\/doi.org\/10.1016\/j.xkme.2022.100475","DOI":"10.1016\/j.xkme.2022.100475"},{"key":"ref11","unstructured":"on-line kal\u2019kulyator veroyatnosti dostizheniya celevogo diapazona paratgormona (300-600 pg\/ml). (In Russ.) \u0414\u043e\u0441\u0442\u0443\u043f\u043d\u043e \u043f\u043e: https:\/\/parshinaev.shinyapps.io\/PTH_lowering_with_etelcalcetide\/. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 29.03.25"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Carro B, Navarro-Gonz\u00e1lez JF, Ortiz A et al. Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis. Nephrol Dial Transplant. 2023;38(11):2589-2597. doi: https:\/\/doi.org\/10.1093\/ndt\/gfad122","DOI":"10.1093\/ndt\/gfad122"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Mart\u00edn JL, Mart\u00ednez-Camblor P, Dionisi MP et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30(9):1542-51. doi: https:\/\/doi.org\/10.1093\/ndt\/gfv099","DOI":"10.1093\/ndt\/gfv099"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Lamina C, Kronenberg F, Stenvinkel P et al. Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort. Nephrol Dial Transplant. 2020;35(3):478-487. doi: https:\/\/doi.org\/10.1093\/ndt\/gfz060","DOI":"10.1093\/ndt\/gfz060"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Cozzolino M, Shilov E, Li Z, Fukagawa M et al. Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America. Adv Ther. 2020;37(6):2748-2762. doi: 1 https:\/\/doi.org\/0.1007\/s12325-020-01359-1","DOI":"10.1007\/s12325-020-01359-1"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Fusaro M, Barbuto S, Gallieni M et al. Real-world usage of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices. Clin Kidney J. 2023;17(1):sfad290. doi: https:\/\/doi.org\/10.1093\/ckj\/sfad290","DOI":"10.1093\/ckj\/sfad290"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Block GA, Bushinsky DA, Cunningham J et al. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA. 2017;317(2):146-155. doi: https:\/\/doi.org\/10.1001\/jama.2016.19456","DOI":"10.1001\/jama.2016.19456"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Block GA, Bushinsky DA, Cheng S et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017;317(2):156-164. doi: https:\/\/doi.org\/10.1001\/jama.2016.19468","DOI":"10.1001\/jama.2016.19468"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"EVOLVE Trial Investigators; Chertow GM, Block GA, Correa-Rotter R et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482-94. doi: https:\/\/doi.org\/10.1056\/NEJMoa1205624","DOI":"10.1056\/NEJMoa1205624"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Zemchenkov A. How has EVOLVE evolved. Single study review. Nephrology and Dialysis. 2017;19(3):342-358. (in Russ)","DOI":"10.28996\/1680-4422-2017-3-342-358"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Bernardor J, De Mul A, Bacchetta J, Schmitt CP. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients. Curr Osteoporos Rep. 2023;21(2):193-204. doi: https:\/\/doi.org\/10.1007\/s11914-023-00782-x","DOI":"10.1007\/s11914-023-00782-x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Goto S, Hamano T, Fujii H et al. Hypocalcemia and cardiovascular mortality in cinacalcet users. Nephrol Dial Transplant. 2024;39(4):637-647. doi: https:\/\/doi.org\/10.1093\/ndt\/gfad213","DOI":"10.1093\/ndt\/gfad213"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Block GA, Bushinsky DA, Cunningham J et al. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA. 2017;317(2):146-155. doi: https:\/\/doi.org\/10.1001\/jama.2016.19456","DOI":"10.1001\/jama.2016.19456"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Block GA, Bushinsky DA, Cheng S et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017;317(2):156-164. doi: https:\/\/doi.org\/10.1001\/jama.2016.19468","DOI":"10.1001\/jama.2016.19468"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Shutov EV, Kotlyarova GV, Lysenko KM et al. Efficacy and safety of etelcalcetide compared with cinacalcet in patients received hemodialysis with secondary hyperparathyroidism. Results from a prospective randomized trial. Clinical Nephrology. 2021;(2):30-34. (in Russ). doi: https:\/\/doi.org\/10.18565\/nephrology.2021.2.34-40","DOI":"10.18565\/nephrology.2021.2.34-40"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Khairallah P, Cherasard J, Sung J et al. Changes in Bone Quality after Treatment with Etelcalcetide. Clin J Am Soc Nephrol. 2023;18(11):1456-1465. doi: https:\/\/doi.org\/10.2215\/CJN.0000000000000254","DOI":"10.2215\/CJN.0000000000000254"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"D\u00f6rr K, Kammerlander A, Lauriero F et al. Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis-a post-hoc analysis of a randomized, controlled trial. J Cardiovasc Magn Reson. 2023;25(1):62. doi: https:\/\/doi.org\/10.1186\/s12968-023-00975-4","DOI":"10.1186\/s12968-023-00975-4"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Villabrille S, Mart\u00edn-Carro B, Mart\u00edn-V\u00edrgala et al. Novel Biomarkers of Bone Metabolism. Nutrients. 2024;16(5):605. doi: https:\/\/doi.org\/10.3390\/nu16050605","DOI":"10.3390\/nu16050605"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Freitas P, Pereira L. Etelcalcetide: What we know eight years since its approval. Nefrologia (Engl Ed). 2025;45(2):116-134. doi: https:\/\/doi.org\/10.1016\/j.nefroe.2025.01.010","DOI":"10.1016\/j.nefro.2024.09.004"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Stephens JM, Fox KM, Desai P et al. Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes. Hemodial Int. 2022;26(2):243-254. doi: https:\/\/doi.org\/10.1111\/hdi.12996","DOI":"10.1111\/hdi.12996"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Karaboyas A, Zhao J, Ma J et al. Incorporation of Calcimimetics into ESRD Bundle: Changes in Etelcalcetide Utilization and PTH Control Following End of TDAPA Designation. Clin J Am Soc Nephrol. 2024. doi: https:\/\/doi.org\/10.2215\/CJN.0000000583","DOI":"10.2215\/CJN.0000000583"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Disthabanchong S, Kasempin P, Srisuwarn P et al. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data. PLoS One. 2024;19(5):e0304649. doi: https:\/\/doi.org\/10.1371\/journal.pone.0304649","DOI":"10.1371\/journal.pone.0304649"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Xipell M, Montagud-Marrahi E, Rubio MV et al. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients. Blood Purif. 2019;48(2):106-114. doi: https:\/\/doi.org\/10.1159\/000496562","DOI":"10.1159\/000496562"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13563\/10932","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:17:14Z","timestamp":1769516234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,18]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,18]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13563","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,18]]}}}